Immunotherapy is designed to stimulate the body's own immune system to attack cancer in the setting of regional/advanced kidney cancer. Kidney cancer is very responsive to immunotherapy. IL-2 was the first approved agent for metastatic kidney cancer and UCLA did much of the early work showing some patients can be cured even with advanced disease. While most centers have stopped giving IL-2 due to cost and toxicity, as our team has been involved in IL-2 for 25 years, our program still offers it to select patients. Exciting new immunotherapy agents restore the immune systems activity to attack cancer. Agents such as Nivolimab (PD-1) and Ipilimumab (CTLA-4) are offered in the outpatient setting and may also offer patients a chance for complete disease remission.